Citations

Clear

9383 citation(s) found for "Thomas, PS".

Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica
Hinson, Shannon R., Pittock, Sean J. , Lucchinetti, Claudia F. , Roemer, Shanu F. , Fryer, J.P. , Kryzer, Thomas J., Lennon, Vanda A. , Pittock, S J

Mayo Clinic

Neurology | October 10, 2007 | Volume: 69 | Issue: 24 | Pages: 2221-2231

10.1212/01.wnl.0000289761.64862.ce | PMID 17928579 Get It

Feasibility of an Affected Sibling Pair Study in Ischemic Stroke
Brown, Robert D., Brott, Thomas G. , Hardy, John , Atkinson, Elizabeth J. , O’Brien, Peter C. , Meschia, James F. , Hardy, John

Mayo Clinic

Stroke | October 10, 2007 | Volume: 32 | Issue: 12 | Pages: 2939-2941

10.1161/hs1201.099795 | PMID 11739999 Get It

Background and Purpose — We sought to determine pedigree availability for a concordant sibling pair study of genetic risk factors in ischemic stroke. Methods — Probands with confirmed ischemic stroke were prospectively enrolled. Family histories were obtained by systematic interview. A study neurologist prospectively assigned stroke subtype. Results — Of 310 probands (median age, 75 years; range, 26 to 97 years; 48% women), 75% had at least 1 living sibling; 10%, at least 1 concordant living sibling; 2%, at least 1 concordant sibling living in the same city; and 7%, at least 1 concordant living and 1 discordant living sibling. Likelihood of having a concordant sibling increased significantly with proband age, even after adjustment for sibship size ( P =0.002). Positive family history of stroke was not related to either proband stroke subtype or risk factor profile. Conclusions — Approximately 10 probands were screened to find 1 potentially concordant living sibling. A concordant sibling pair study should be multicentered and enable enrollment of siblings from diverse geographic areas.
Cardiac Rehabilitation/Secondary Prevention Programs
Thomas, Randal J. , Thomas, Randal

Mayo Clinic

Circulation | October 8, 2007 | Volume: 116 | Issue: 15 | Pages: 1644-1646

10.1161/circulationaha.107.728402 | PMID 17923581 Get It

Mucociliary Clearance in Experimental Chronic Sinusitis
Czaja, Judith M., McCaffrey, Thomas V.

Mayo Clinic

American Journal of Rhinology | October 7, 2007 | Volume: 10 | Issue: 5 | Pages: 271-280

10.2500/105065896782159747 Get It

Abnormal mucociliary clearance in the paranasal sinuses is a significant factor in the pathogenesis of sinusitis. This study examined effects of chronic sinusitis on ciliary beat frequency (CBF), mucociliary transport (MCT) velocity, mucociliary transport patterns, and histology of sinus mucosa in rabbits. Two groups of rabbits were studied: uninfected (n = 9) and infected (n = 18). Maxillary sinus ostia in all animals were occluded, and sinuses in the infected group were inoculated with 10 8 cfu of Streptococcus pneumoniae. Chronic sinusitis developed over 6 weeks and was confirmed by histopathology and culture. Evaluation of the MCT mechanism included 1) measurement of CBF using a photometric technique, 2) direct measurement of MCT velocity, and 3) analysis of MCT patterns with inert India ink. In seven of nine (77.8%) uninfected animals, the mean CBF was 11.5 Hz (±.39 Hz) initially and 11.3 Hz (±.32 Hz) 6 weeks after occlusion (P = 0.69). MCT velocity measured 20.6 mm/min (±1.40 mm/min) initially and 16.85 mm/min (±1.96 mm/min) 6 weeks after occlusion (P = 0.16). In the infected group, there were statistically significant decreases in CBF (P < 0.05) and measured MCT velocity (P < 0.05). Examination of MCT in infected animals showed patterns of misdirected flow, pooling, and stagnation. Histopathologic changes included significant losses of ciliated epithelium and mucosal abnormalities consistent with chronic sinusitis. Chronic sinusitis secondary to long-standing bacterial infection leads to alterations in CBF, MCT velocity, and MCT patterns in the paranasal sinuses of rabbits.
Cryopreservation of Human Nasal Ciliated Epithelium
McCaffrey, Thomas V., Kern, Eugene B. , Yang, Bin

Mayo Clinic

American Journal of Rhinology | October 7, 2007 | Volume: 10 | Issue: 5 | Pages: 291-298

10.2500/105065896782159684 Get It

The purpose of this study was to compare the effects on human nasal cilia of various freezing and thawing methods in order to determine a reliable method of cryopreservation. Ten samples each were preserved by a slow freezing and a fast freezing method. All samples were stored in liquid nitrogen (–196°C) for 1 week. The frozen samples were thawed by one of two methods: 1) rapid thawing—37°C water bath for 3–4 minutes; and 2) slow thawing—room temperature for 15 minutes. Prefreeze and postthaw ciliary beat frequency (CBF) was measured. The slow freezing and fast thawing method (SFFT) resulted in the best viability. An additional 10 samples preserved using the SFFT method stored at –70°C to –90°C did not retain ciliary function. Thirty ciliated samples preserved by the SFFT method were examined after freezing in liquid nitrogen (–196°C) for 1 week, 2 weeks, and 1 month. There was no significant decrease in CBF after cryopreservation at –196°C for 1 week or 2 weeks (P> 0.05). As the storage time increased to 1 month, postthaw CBF decreased 7.25 ± 0.87% when compared to the prefreeze CBF (P < 0.05). We conclude that human nasal cilia preserved by SFFT at –196°C retain activity for up to 1 month.
Reversibility of Abnormal Mucociliary Clearance in Experimental Chronic Sinusitis
Czaja, Judith M., McCaffrey, Thomas V.

Mayo Clinic

American Journal of Rhinology | October 7, 2007 | Volume: 10 | Issue: 5 | Pages: 281-290

10.2500/105065896782159666 Get It

Normal mucociliary clearance in the paranasal sinuses must be restored to reverse the effects of chronic sinusitis. This study examined effects of middle meatal antrostomy (MMA) on ciliary beat frequency (CBF), mucociliary transport (MCT) velocity, MCT patterns, and histology of sinus mucosa in rabbits with chronic sinusitis to determine whether objective measures of mucociliary function and histology could be reversed. Two groups of rabbits were compared: uninfected (Group A controls, n = 9) and infected (Group B, n = 11). Maxillary sinus ostia were occluded; 10 8 cfu of Streptococcus pneumoniae were inoculated into sinuses of rabbits in group B, and chronic sinusitis developed. This was confirmed by histopathology and culture 6 weeks after infection. Middle meatal antrostomies were performed in the infected group, and sinuses were studied 6 weeks later. Control animals (Group A) had mean CBF = 11.5 Hz (±.39 Hz). Animals with chronic sinusitis (Group B) had mean CBF = 8.6 Hz (±.24 Hz). This was statistically different from control (P < 0.05). Six weeks following MMA, group B had mean CBF = 12.9 Hz (±.75 Hz). This was not different from control. There were changes in MCT velocity that correlated with the CBF (r = 0.72). Examination of MCT patterns after MMA demonstrated minimal pooling and stagnation; however, small areas of misdirected flow persisted. After MMA, there were decreased numbers of inflammatory and goblet cells and increased numbers of ciliated epithelial cells. This study demonstrated that mucociliary clearance and histological changes seen in rabbits with chronic sinusitis are reversed by MMA.
Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia
Huang, Steven K. , Wettlaufer, Scott H., Hogaboam, Cory M. , Flaherty, Kevin R. , Colby, Thomas V. , Toews, Galen B., Peters‐Golden, Marc , Martínez, Fernando J. , Myers, Jeffrey L. , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 4, 2007 | Volume: 177 | Issue: 1 | Pages: 66-74

10.1164/rccm.200706-963oc | PMID 17916807 Get It

Abstract Rationale Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. Objectives To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Methods Fibroblasts were grown in vitro from well characterized control (n = 7), UIP (n = 17), or other DPLD (n = 13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Measurements and Main Results Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 nonfibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2, whereas other DPLD fibroblasts manifested a degree of resistance intermediate to control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. Conclusions The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.
Modulation of Ciliary Beat Frequency in the Upper Airway by Prostaglandins
Franco, Ramon A. , Czaja, Judith M., McCaffrey, Thomas V., Schlosser, Rodney J.

Mayo Clinic

American Journal of Rhinology | October 3, 2007 | Volume: 10 | Issue: 4 | Pages: 229-234

10.2500/105065896782103081 Get It

Prostaglandins are ubiquitous within tissues and participate in several local regulatory functions. Previous reports have presented conflicting evidence on their role in ciliary activity in the upper airway. We studied the in vitro effects of prostaglandin E 2 (PGE 2 ) and a prostaglandin I 2 analog (Iloprost) on the ciliary beat frequency (CBF) of human adenoid explants and rabbit sinus mucosa. Tissue explants were maintained in culture at 35°C. PGE 2 or Iloprost was added to the culture media at concentrations of 10 –6 , to 10 –12 M. CBF was determined using phase contrast microscopy and microphotometry. PGE 2 increased CBF with a maximum increase of 54.6% in rabbit mucosa (P < 0.01) and 20.0% in human adenoid (P < 0.009). Iloprost increased CBF with a maximum increase of 35.2% in rabbit mucosa (P < 0.02) and 16.4% in human adenoid (P < 0.03). Induced production of endogenous prostaglandins was determined by treating specimens with a cyclooxygenase inhibitor (diclofenac) prior to addition of PGE 2 or Iloprost. Diclofenac had no effect on the ciliostimulatory effects of PGE 2 (P > 0.36), however it significantly decreased the ciliostimulatory effect of Iloprost (P < 0.037). Both PGE 2 and Iloprost stimulate ciliary motility, yet the action of PGE 2 is direct, whereas Iloprost stimulates cilia by release of endogenous prostaglandins in both the human and rabbit.
Vasopeptidase Inhibitors
Corti, Roberto , Burnett, John C. , Rouleau, Jean L. , Lüscher, Thomas F. , Ruschitzka, Frank T.

Mayo Clinic

Circulation | September 28, 2007 | Volume: 104 | Issue: 15 | Pages: 1856-1862

10.1161/hc4001.097191 | PMID 11591626 Get It

The cardiovascular system is regulated by hemodynamic and neurohumoral mechanisms. These regulatory systems play a key role in modulating cardiac function, vascular tone, and structure. Although neurohumoral systems are essential in vascular homeostasis, they become maladaptive in disease states such as hypertension, coronary disease, and heart failure. The clinical success of ACE inhibitors has led to efforts to block other humoral systems. Neutral endopeptidase (NEP) is an endothelial cell surface zinc metallopeptidase with similar structure and catalytic site. NEP is the major enzymatic pathway for degradation of natriuretic peptides, a secondary enzymatic pathway for degradation of kinins, and adrenomedullin. The natriuretic peptides can be viewed as endogenous inhibitors of the renin angiotensin system. Inhibition of NEP increases levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) of myocardial cell origin, and C-type natriuretic peptide (CNP) of endothelial cell origin as well as bradykinin and adrenomedullin. By simultaneously inhibiting the renin-angiotensin-aldosterone system and potentiating the natriuretic peptide and kinin systems, vasopeptidase inhibitors reduce vasoconstriction, enhance vasodilation, improve sodium/water balance, and, in turn, decrease peripheral vascular resistance and blood pressure and improve local blood flow. Within the blood vessel wall, this leads to a reduction of vasoconstrictor and proliferative mediators such as angiotensin II and increased local levels of bradykinin (and, in turn, nitric oxide) and natriuretic peptides. Preliminary clinical experiences with vasopeptidase inhibitors are encouraging. Thus, the combined inhibition of ACE and neutral endopeptidase is a new and promising approach to treat patients with hypertension, atherosclerosis, or heart failure.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Raza, Azra , Reeves, James A. , Feldman, Eric J. , Dewald, Gordon W., Bennett, John M. , Deeg, H. Joachim , Dreisbach, Luke, Schiffer, Charles A. , Stone, Richard M. , Greenberg, Peter L. , Curtin, Peter , Klimek, Virginia M., Shammo, Jamile M. , Thomas, Deborah A. , Schmidt, M., Wride, Kenton, Zeldis, Jerome B. , List, Alan F. , Knight, Robert

Mayo Clinic

Blood | September 25, 2007 | Volume: 111 | Issue: 1 | Pages: 86-93

10.1182/blood-2007-01-068833 | PMID 17893227 Get It

Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities. We report results of a multicenter, phase 2 trial evaluating lenalidomide therapy for transfusion-dependent patients with low- or int-1–risk MDS without deletion 5q. Eligible patients had 50 000/mm3 or more platelets and required 2 U or more RBCs within the previous 8 weeks; 214 patients received 10 mg oral lenalidomide daily or 10 mg on days 1 to 21 of a 28-day cycle. The most common grade 3/4 adverse events were neutropenia (30%) and thrombocytopenia (25%). Using an intention-to-treat analysis, 56 (26%) patients achieved transfusion independence (TI) after a median of 4.8 weeks of treatment with a median duration of TI of 41.0 weeks. In patients who achieved TI, the median rise in hemoglobin was 32 g/L (3.2 g/dL; range, 10-98 g/L [1.0-9.8 g/dL]) from baseline. A 50% or greater reduction in transfusion requirement occurred in 37 additional patients, yielding a 43% overall rate of hematologic improvement (TI response +‖≥ 50% reduction in transfusion requirement). Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1–risk MDS who lack the deletion 5q karyotypic abnormality. This study is registered at www.clinicaltrials.gov as no. NCT00064974.